RECHEM
Welcome to our website!|Hot Line: 86-21-31433387|E-mail: sales@rechemscience.com
Products Category
Contact Us
| Tel: | +86-21-31433387 |
| +86-15618786686 | |
| Email: | sales@rechemscience.com |
| info@rechemscience.com | |
| QQ: | 1369748377 |
| Skype: | sales@rechemscience.com |
Home > Products
| Cat.No. | Product name | Product Description |
| R10284 | Nintedanib; BIBF1120 Intermediate2 | Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, |
| R10285 | Nintedanib; BIBF1120 Intermediate3 | Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, |
| R10286 | Nintedanib; BIBF1120 Intermediate4 | Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, |
| R10287 | TR700; DA7157; Torezolid | Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti |
| R10288 | TR700; DA7157; Torezolid phosphate | Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti |
| R10289 | TR700; DA7157; Torezolid Intermediate1 | Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti |
| R10290 | TR700; DA7157; Torezolid Intermediate2 | Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti |
| R10291 | TR700; DA7157; Torezolid Intermediate3 | Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti |
| R10292 | TR700; DA7157; Torezolid Intermediate4 | Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti |
| R10293 | TR700; DA7157; Torezolid Intermediate5 | Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti |
| R10294 | TR700; DA7157; Torezolid Intermediate6 | Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti |
| R10296 | Afatinib; BIBW2992 | Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85 |
| R10297 | Afatinib BIBW2992 Intermediate1 | Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85 |
| R10298 | Afatinib BIBW2992 Intermediate2 | Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85 |
| R10299 | Afatinib BIBW2992 Intermediate3 | Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85 |
| R10300 | Afatinib BIBW2992 Intermediate4 | Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85 |
| R10301 | Afatinib BIBW2992 Intermediate5 | Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85 |
| R10302 | CO1686 Intermediate1 | Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibit |
| R10303 | CO1686 Intermediate2 | Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibit |
| R10304 | CO1686 Intermediate3 | Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibit |
| R10305 | HKI272; HKI272; Neratinib Intermediate1 | Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 5 |
| R10306 | HKI272; HKI272; Neratinib Intermediate2 | Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 5 |
| R10307 | HKI272; HKI272; Neratinib Intermediate3 | Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 5 |
| R10308 | HKI272; HKI272; Neratinib Intermediate4 | Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 5 |
| R10309 | E7080; E7080; Lenvatinib Intermediate1 | Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 5 |
